ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Global Health Limited granted 10,000 ESOPs at Rs. 960 each under its LTIP 2024 Plan. The ₹0.96 Crore grant aims to reward and retain key talent.
Global Health Ltd has scheduled a board meeting on May 14, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for FY 2025-26. Consequently, the trading window is closed until 48 hours post-declaration.
Global Health Limited (Medanta) entered a Business Transfer Agreement to acquire an 80-bed Cancer Hospital in Indore for ₹30 Crore. The facility, located near Medanta's existing Indore hospital, adds comprehensive oncology services and strengthens its Central India presence. The transaction includes the assignment of a long-term lease.
Global Health Limited (Medanta) approved the acquisition of a 79-bedded cancer care hospital in Indore for ₹30 Crore. The facility, currently operated by AIOPL, will be integrated into the Medanta network by September 2026. This strategic expansion strengthens Medanta's oncology presence and regional footprint in close proximity to its existing Indore facility.
Global Health Limited (Medanta) has agreed to acquire a 79-bedded cancer care hospital in Indore from AIOPL for ₹30 Crore. The transaction, expected to close by September 30, 2026, expands Medanta's healthcare network into the Indore market. The acquisition is subject to customary statutory approvals.
Global Health Limited (Medanta) allotted 61,500 equity shares under its employee stock option scheme on April 22, 2026. This increases the company's total paid-up share capital from 268,790,382 to 268,851,882 equity shares.
Global Health Ltd (Medanta) allotted 61,500 equity shares at Rs. 1,082 per share (totaling ₹6.66 Crore) to the GHL Employees Welfare Trust under its ESOP scheme. Post-allotment, the company's paid-up share capital increased to ₹53.77 Crore. These shares rank pari-passu with existing equity and support employee long-term incentives.